pneumonia%20-%20hospital-acquired
PNEUMONIA - HOSPITAL-ACQUIRED
Hospital-acquired pneumonia (HAP) is defined as pneumonia occurring ≥48 hours after admission and excluding any infection that is incubating at the time of admission.
Ventilator-associated pneumonia (VAP) is described as pneumonia occurring >48-72 hours after endotracheal intubation and within 48 hours after removal of endotracheal tube.
Early-onset HAP or VAP is the pneumonia occurring within the first 4 days of hospitalization that may be cause by antibiotic-sensitive bacteria that usually carries a better diagnosis.
Late-onset HAP or VAP is the pneumonia occurring after ≥5 days. It is likely caused by multidrug-resistant pathogens associated with increased mortality and morbidity.

Pneumonia%20-%20hospital-acquired Treatment

Principles of Therapy

Initiation of Empiric Therapy 

  • Antibiotic therapy should be started within 4 hours after diagnosis of hospital-acquired pneumonia (HAP) has been established
  • Prompt initiation of appropriate initial antibiotic therapy can decrease mortality
  • When deciding to start empiric therapy, treatment should be microbiologically-defined rather than empiric therapy-based
  • All patients w/ HAP & ventilator-associated pneumonia (VAP) should be treated initially w/ intravenous (IV) therapy, but switch to oral therapy may be considered in some patients who are responding to therapy

Choice of Antibiotics for Empiric Therapy

  • Empiric choice of antibiotic agents should take into consideration the local microbiology, availability, cost & formulary restrictions
    • Initial empiric therapy should be adapted to local patterns of antibiotic resistance & when possible each ICU should collect this information on a regular basis
  • Empiric therapy also needs to take into consideration what therapies the patient has received within the last 2 weeks
    • If patient has received antibiotics recently for a different infection, therapy should utilize an agent from a different antibiotic class for resistance is predicted by recent antibiotic exposure
  • An antibiotic course of 5-10 days is recommended for patients w/ confirmed HAP
  • Not only should appropriate antibiotics be used, they should be used at the optimum doses & correct route of administration
  • A major risk factor for mortality & increasing length of hospital stay is the administration of inappropriate antibiotics

Pharmacotherapy

Empiric Therapy in Patients w/ No Risk Factors for Multidrug-resistant (MDR) Pathogens
  • Narrow-spectrum antibiotics are recommended for patients w/ low-risk HAP/VAP
Possible Pathogens
  • Streptococcus pneumoniae
    • Local resistance patterns should be followed because the frequency of Penicillin-resistant & multidrug- resistant S pneumoniae is increasing
    • An aminopenicillin at appropriate dose remains the treatment of choice for most Penicillin-resistant S pneumoniae w/ MIC ≤2 mcg/mL
  • Other potential pathogens
    • Haemophilus influenzae, Methicillin-sensitive Staphylococcus aureus (MSSA)
    • Gram-negative bacilli (eg Escherichia coli, Klebsiella pneumoniae, Enterobacter sp, Proteus sp, Serratia marcescens)
Hospital-acquired Pneumonia (HAP)/Ventilator-associated Pneumonia (VAP)
  • Low-risk HAP patients without risk factors for MRSA will likely respond to monotherapy w/ 1 of the following agents:
    • Beta-lactam/beta-lactamase inhibitor combinations (eg Piperacillin/tazobactam)
    • Nonpseudomonal 3rd generation cephalosporins (eg Ceftriaxone, Cefotaxime, or Cefepime)
    • Quinolones (eg Levofloxacin or Moxifloxacin)
  • May consider treatment w/ Ertapenem, Imipenem or Meropenem in patients w/ increased risk for extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacillus & w/ contraindications to Cefepime
  • If MSSA is confirmed, may consider treatment w/ Oxacillin, Nafcillin, or Cefazolin
Empiric Therapy in Patients w/ Risk Factors for Multidrug-resistant (MDR) Pathogens
  • Broad-spectrum antibiotics w/ activity against MDR pathogens are recommended for patients w/ high risk HAP/VAP
  • Those at risk for the below organisms should initially receive a combination of broad-spectrum coverage
    • This will decrease the risk of inappropriate antibiotic therapy
  • Concurrent treatment w/ 2-3 drugs should be considered in patients w/ late-onset VAP
Possible Pathogens
  • All the pathogens listed in section Empiric Therapy in Patients w/ No Risk Factors for MDR Pathogens are possible causative organisms
Multidrug-resistant (MDR) pathogens
  • Pseudomonas aeruginosa, K pneumoniae, Acinetobacter sp, & Stenotrophomonas maltophilia
  • Extended-spectrum beta-lactamase-producing (ESBL) Enterobacteriaceae
  • MRSA should be considered if MRSA risk factors (eg antibiotic therapy prior to onset of pneumonia, prolonged hospital stay) are present, presence of severe pneumonia/sepsis &/or if there is high local incidence
  • Legionella pneumophila
Ventilator-associated Pneumonia (VAP)
  • Vancomycin or Linezolid is recommended for patients at high-risk for MRSA (>10-20% methicillin-resistant S aureus isolates)
    • 2 antipseudomonal antibiotics are recommended if w/ >10% resistance to recommended monotherapy & for ICU patients
      • Antipseudomonal beta-lactam/beta-lactamase inhibitor Piperacillin/tazobactam
      • Antipseudomonal carbapenems Imipenem or Meropenem
      • Antipseudomonal 3rd- & 4th-generation cephalosporins Cefepime or Ceftazidime
      • Aztreonam: May be considered if w/ treatment failure w/ other agents
  • If combination therapy is indicated, an aminoglycoside (eg Amikacin, Gentamicin or Tobramycin) or antipseudomonal quinolone (Ciprofloxacin or Levofloxacin) may be considered as secondary agents
    • Aminoglycoside therapy should be discontinued once susceptibility to beta-lactam therapy is confirmed & if w/ clinical improvement
    • Use of polymyxins (eg Colistin, Polymyxin B) instead of an aminoglycoside or quinolone may be considered in ICU patients w/ Acinetobacter etiology or if high prevalence of multidrug resistance is present; should not be used if other Gram-negative antibiotics are available
  • Telavancin may be considered in patients w/ MRSA pneumonia when neither Linezolid nor Vancomycin can be used
Hospital-acquired Pneumonia (HAP)
  • Monotherapy may be sufficient for patients at high-risk but w/ >90% Gram-negative antibiotic activity
  • Combination therapy w/ 2 different classes of antibiotics is recommended for HAP patients w/ increased risk for Pseudomonas sp or other Gram-negative infection, patients who received IV antibiotics within the last 90 days, or those at high-risk for mortality
  • Recommended therapy for HAP patients at high-risk for MRSA & Gram-negative pathogens but low-risk formortality:
    • Antipseudomonal beta-lactam/beta-lactamase inhibitor Piperacillin/tazobactam
    • Antipseudomonal carbapenems Imipenem or Meropenem
    • Antipseudomonal 3rd- & 4th-generation cephalosporins Cefepime or Ceftazidime
    • Antipseudomonal fluoroquinolone (eg Ciprofloxacin, Levofloxacin): In combination w/ another drug class
    • Aztreonam: May be considered if w/ treatment failure w/ other agents
  • Use of an aminoglycoside (eg Amikacin, Gentamicin, Tobramycin) in combination w/ another drug class maybe considered in patients who received IV antibiotics within the last 90 days
  • Addition of Vancomycin or Linezolid is recommended for patients at high-risk for MRSA (>10-20% methicillin-resistant S aureus isolates)
    • Telavancin may be considered in patients w/ MRSA pneumonia when neither Linezolid nor Vancomycin can be used
  • If MSSA is confirmed, may consider treatment w/ Oxacillin, Nafcillin, or Cefazolin
Specific Pathogens

Pseudomonal Infection

  • Definitive therapy based on susceptibility tests is recommended instead of empiric therapy if positive for P aeruginosa infection
  • Monotherapy based on susceptibility test is preferred in HAP/VAP patients w/ pseudomonal infection without comorbidities rather than combination therapy 
    • For patients w/ comorbidities & at high-risk for mortality w/ known antibiotic susceptibility test result, combination of 2 antibiotics based on susceptibility test is recommended
  • Choice of specific agents if Pseudomonas sp is found should be based on the results of sensitivity testing
  • Pseudomonas sp can rapidly develop resistance to all classes of antibiotics & resistance develops in 30-50% of patients who receive monotherapy
    • Evidence is lacking to show that this does not occur when combination therapy is used but there is limited data showing patients w/ Pseudomonas sp bacteremia are less likely to die when combination therapy is used
  • Polymyxins may be given as an alternative drug if patient remains unresponsive
Acinetobacter sp
  • Acinetobacter sp have native resistance to many classes of antibiotics
  • Carbapenems, Sulbactam (eg Ampicillin/sulbactam or Cefoperazone/sulbactam) & Polymyxins B or E (eg Colistin) tend to be the most consistently effective agents
    • Carbapenem-resistant clones can be a problem & therefore, optimal dosing should be used
    • IV Polymyxins (eg Colistin, Polymyxin B) are recommended for HAP/VAP patients w/ carbapenem-resistant strains; adjunctive inhaled Colistin may also be considered
  • Combination therapy of Imipenem plus Ampicillin/sulbactam or Sulbactam alone is recommended
  • Acinetobacter sp; however, Netilmicin has been shown to be effective in 50% of strains based on an Asian study
Extended-spectrum beta-lactamases (ESBL) Enterobacteriaceae
  • Therapy based on antibiotic susceptibility testing & presence of comorbidities are recommended 
  • Carbapanems are generally a reliable choice
  • Piperacillin/tazobactam has been proven to be highly active in vitro against K pneumoniae & E coli
  • Cephalosporin susceptibility is variable, therefore 3rd- & 4th-generation cephalosporins should not be used as monotherapy if this organism is suspected
    •  If Enterobacter sp is suspected, 3rd-generation cephalosporins should be avoided because of possible emergence of resistance during treatment
  • If L pneumophila is suspected, antibiotic regimen should include a macrolide (eg Azithromycin) or quinolone (eg Ciprofloxacin or Levofloxacin) rather than an aminoglycoside
Methicillin-resistant Staphylococcus aureus (MRSA)
  • Vancomycin or Linezolid is recommended as1st-line agent for MRSA
  • Linezolid has been shown to have comparable efficacy to Vancomycin in patients w/ HAP
  • Telavancin may be considered if Vancomycin & Linezolid are unavailable or w/ treatment failure but benefits should outweigh the risk
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 6 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.
Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.